128 related articles for article (PubMed ID: 16930139)
21. Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis.
Bock O; Neusch M; Büsche G; Mengel M; Kreipe H
Eur J Haematol; 2004 Apr; 72(4):239-44. PubMed ID: 15089760
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
23. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.
Stauffer Larsen T; Hasselbalch HC; Pallisgaard N; Møller MB
APMIS; 2007 Nov; 115(11):1267-73. PubMed ID: 18092959
[TBL] [Abstract][Full Text] [Related]
25. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
[TBL] [Abstract][Full Text] [Related]
26. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S
Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778
[TBL] [Abstract][Full Text] [Related]
27. Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle?
Bock O; Hussein K; Kreipe H
Curr Stem Cell Res Ther; 2007 Sep; 2(3):253-63. PubMed ID: 18220909
[TBL] [Abstract][Full Text] [Related]
28. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
29. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
30. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
31. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
32. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence.
Shide K; Shimoda K; Kamezaki K; Kakumitsu H; Kumano T; Numata A; Ishikawa F; Takenaka K; Yamamoto K; Matsuda T; Harada M
Leuk Res; 2007 Aug; 31(8):1077-84. PubMed ID: 17011030
[TBL] [Abstract][Full Text] [Related]
33. Megakaryocytic expression of miRNA 10a, 17-5p, 20a and 126 in Philadelphia chromosome-negative myeloproliferative neoplasm.
Hussein K; Dralle W; Theophile K; Kreipe H; Bock O
Ann Hematol; 2009 Apr; 88(4):325-32. PubMed ID: 18773208
[TBL] [Abstract][Full Text] [Related]
34. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
35. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
36. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases.
Tognon R; Gasparotto EP; Leroy JM; Oliveira GL; Neves RP; Carrara Rde C; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Velano CE; Simões BP; Alberto FL; Miyashiro K; de Souza AM; Amarante-Mendes GP; de Castro FA
J Clin Pathol; 2011 Jan; 64(1):75-82. PubMed ID: 21045235
[TBL] [Abstract][Full Text] [Related]
38. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
39. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
40. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
